丰原药业(000153) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 817,709,972.47, representing an 8.19% increase year-on-year[9] - Net profit attributable to shareholders was CNY 18,575,738.62, a 1.21% increase compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 94.26% to CNY 1,078,199.73[9] - Basic earnings per share rose by 2.76% to CNY 0.0595[9] - The company's net profit margin for Q3 2019 was approximately 0.3%, down from the previous year's margin, indicating increased cost pressures[37] - The net profit for Q3 2019 was CNY 18,440,295.65, slightly up from CNY 18,327,450.19 in Q3 2018, representing an increase of 0.6%[39] - The total profit for Q3 2019 was CNY 26,985,952.70, down from CNY 27,379,538.73 in Q3 2018, indicating a decrease of 1.4%[39] - The company's operating profit for Q3 2019 was CNY 26,124,836.07, compared to CNY 27,020,180.34 in the previous year, reflecting a decline of 3.3%[39] - The comprehensive income total for Q3 2019 was CNY 13,502,697.91, down from CNY 22,889,408.16 in the same quarter last year, a decrease of 41.0%[40] - The total comprehensive income attributable to the parent company for Q3 2019 was CNY 13,638,140.88, compared to CNY 22,915,946.56 in Q3 2018, indicating a decrease of 40.5%[40] Assets and Liabilities - Total assets increased by 10.79% to CNY 3,332,455,801.12 compared to the end of the previous year[9] - The total current assets as of September 30, 2019, amounted to CNY 1,924,597,432.26, an increase from CNY 1,588,155,611.28 at the end of 2018[30] - Total assets as of September 30, 2019, reached CNY 2,717,976,429.55, compared to CNY 2,425,375,079.92 at the end of 2018, marking an increase of 12.1%[35] - Total liabilities increased to CNY 1,814,593,035.00 from CNY 1,485,847,041.51, reflecting a rise of 22.1% year-over-year[36] - The company's equity attributable to shareholders was CNY 903,383,394.55, down from CNY 939,528,038.41, indicating a decrease of 3.8%[36] - The total liabilities included accounts payable of CNY 416,992,792.51, down from CNY 453,589,579.31[31] - The company reported a total asset value of CNY 2,425,375,079.92[65] - The company’s total liabilities included short-term borrowings of ¥366,000,000.00[60] Cash Flow - The company reported a net cash flow from operating activities of CNY 39,425,467.07, down 15.07% year-on-year[9] - The net cash flow from investing activities worsened by 91.93% to -¥147,280,109.67, reflecting higher cash payments for fixed assets and long-term investments[17] - The net cash flow from operating activities for Q3 2019 was ¥39,425,467.07, a decrease of 15.5% compared to ¥46,421,123.98 in Q3 2018[53] - Total cash inflow from operating activities was ¥706,344,215.64, up 12.3% from ¥629,193,592.74 in the previous year[56] - Cash outflow from operating activities totaled ¥657,971,082.14, an increase of 6.1% compared to ¥620,056,222.25 in the same period last year[56] - The net cash flow from financing activities was ¥106,002,870.47, compared to ¥97,222,092.61 in Q3 2018, reflecting a growth of 9.2%[54] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,646[12] - The top ten shareholders held a combined 32.73% of the company's shares, with the largest shareholder owning 11.48%[12] Research and Development - Research and development expenses decreased by 34.46% to ¥39,528,922.70 compared to the same period last year[17] - Research and development expenses for Q3 2019 were CNY 13,242,306.47, a decrease of 54.7% compared to CNY 29,227,019.40 in the previous year[37] - Research and development expenses for Q3 2019 were CNY 5,390,073.16, a significant decrease of 63.1% from CNY 14,611,299.85 in Q3 2018[42] Other Income and Expenses - Other income increased by 559.72% to ¥30,735,361.48, largely due to higher government subsidies related to daily activities[17] - The company experienced a significant increase in other income, which rose to CNY 17,058,487.36 in Q3 2019 from CNY 1,043,735.88 in Q3 2018[39]